What you should know:
1. The merger also included a funding round that raised $22 million.
2. The company is advancing two therapies: larazotide, a therapy for celiac disease currently in a phase 3 trial, and GLP-1, which treats short bowel syndrome.
3. John Temperato will lead a management team that has brought a combined 15 drugs to market.
More articles on surgery centers:
Life after ramp-up: How COVID-19 will change ASCs forever
3 ASC nurses join COVID-19 front lines in New York
4 hospitals, health systems opening ASCs
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
